Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
Market Spotlight: Acute Lymphoblastic Leukemia (ALL)
Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a rare blood cancer characterized by rapid proliferation and accumulation of immature lymphoid cells in the bone marrow, peripheral blood, and other organs.
Author: Informa Pharma Intelligence
Publisher: Datamonitor Healthcare
This Market Spotlight report covers the Acute Lymphoblastic Leukemia (ALL) market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, regulatory events, probability of success, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.
- Datamonitor Healthcare estimates that in 2018, there were 86,600 incident cases of ALL worldwide, and expects that number to increase to 93,500 incident cases by 2027.
- Approved drugs in the ALL space focus on a wide variety of targets. The majority of these therapies are administered via the intravenous route, with the remaining products being available in oral and intramuscular formulations.
- The greatest proportion of industry-sponsored drugs in active clinical development for ALL are in Phase I, with only one drug in Phase III.
- Therapies in development for ALL focus on a wide variety of targets. The majority of pipeline drugs in development are administered via the intravenous route, with the remainder being tested in oral formulations.
- The only high-impact upcoming event for drugs in the ALL space is topline Phase II trial results for Isatuximab. The overall likelihood of approval of a Phase I hematologic asset is 9.6%, and the average probability a drug advances from Phase III is 58.3%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
- There have been 40 licensing and asset acquisition deals involving ALL drugs during 2014–19. The $1,220m strategic collaboration agreement signed in 2018 between Fate Therapeutics and Ono Pharmaceutical for the joint development and commercialization of two off-the-shelf CAR-T cell product candidates was the largest deal.
- The distribution of clinical trials across Phase I–IV indicates that the vast majority of trials for ALL have been in the early and mid-phases of development, with 91% of trials in Phase I–II, and only 9% in Phase III–IV.
- The US has a substantial lead in the number of ALL clinical trials globally. France leads the major EU markets, while China has the top spot in Asia.
- Clinical trial activity in the ALL space is dominated by completed trials. Novartis has the highest number of completed clinical trials for ALL, with 41 trials.
- Novartis leads industry sponsors with the highest overall number of clinical trials for ALL.
7 KEY TAKEAWAYS
8 DISEASE BACKGROUND
8 Patient segmentation
9 Risk factors
11 TKI therapy
12 Radiation therapy
12 Stem cell transplant
16 MARKETED DRUGS
20 PIPELINE DRUGS
27 RECENT EVENTS AND ANALYST OPINION
27 Blincyto for ALL (September 24, 2019)
28 Copiktra for ALL (July 25, 2019)
29 KTE-X19 for ALL (June 1, 2019)
31 Copiktra for ALL (March 6, 2019)
32 Marqibo for ALL (January 17, 2019)
33 AFM11 for ALL (December 3, 2018)
34 KTE-X19 for ALL (December 3, 2018)
35 AUTO3 for ALL (December 2, 2018)
37 Xpovio for ALL (December 1, 2018)
37 AFM11 for ALL (October 8, 2018)
38 ERY-ASP for ALL (June 24, 2018)
39 KTE-X19 for ALL (June 4, 2018)
42 KEY UPCOMING EVENTS
43 KEY REGULATORY EVENTS
43 Japan Approvals Include World-First For Skyrizi, Kymriah As Asia’s First CAR-T
43 Measuring ‘Minimal Residual Disease’ With NGS
44 PROBABILITY OF SUCCESS
45 LICENSING AND ASSET ACQUISITION DEALS
45 CASI Acquires Global Rights To Juventas’ Anti-CD19 Therapy
46 PARENT PATENTS
47 REVENUE OPPORTUNITY
49 CLINICAL TRIAL LANDSCAPE
50 Sponsors by status
51 Sponsors by phase
52 Recent events
54 Prescription information
LIST OF FIGURES
15 Figure 1: Trends in incident cases of ALL, 2018–27
20 Figure 2: Overview of pipeline drugs for ALL in the US
20 Figure 3: Pipeline drugs for ALL, by company
21 Figure 4: Pipeline drugs for ALL, by drug type
21 Figure 5: Pipeline drugs for ALL, by classification
28 Figure 6: Blincyto for ALL (September 24, 2019): Phase III – Pediatric (1st Relapse)
31 Figure 7: KTE-X19 for ALL (June 1, 2019): Phase I/II – ZUMA-3 (r/r Adults)
35 Figure 8: KTE-X19 for ALL (December 3, 2018): Phase I/II – ZUMA-3 (r/r Adults)
41 Figure 9: KTE-X19 for ALL (June 4, 2018): Phase I/II – ZUMA-3 (r/r Adults)
42 Figure 10: Key upcoming events in ALL
44 Figure 11: Probability of success in the ALL pipeline
45 Figure 12: Licensing and asset acquisition deals in ALL, 2014–19
46 Figure 13: Parent patents in ALL
49 Figure 14: Clinical trials in ALL
49 Figure 15: Top 10 drugs for clinical trials in ALL
50 Figure 16: Top 10 companies for clinical trials in ALL
50 Figure 17: Trial locations in ALL
51 Figure 18: ALL trials sponsors by status
52 Figure 19: ALL trials sponsors, by phase
LIST OF TABLES
14 Table 1: Incident cases of ALL, 2018–27
17 Table 2: Marketed drugs for ALL
22 Table 3: Pipeline drugs for ALL in the US
27 Table 4: Blincyto for ALL (September 24, 2019)
29 Table 5: Copiktra for ALL (July 25, 2019)
30 Table 6: KTE-X19 for ALL (June 1, 2019)
31 Table 7: Copiktra for ALL (March 6, 2019)
32 Table 8: Marqibo for ALL (January 17, 2019)
33 Table 9: AFM11 for ALL (December 3, 2018)
34 Table 10: KTE-X19 for ALL (December 3, 2018)
36 Table 11: AUTO3 for ALL (December 2, 2018)
37 Table 12: Xpovio for ALL (December 1, 2018)
38 Table 13: AFM11 for ALL (October 8, 2018)
39 Table 14: ERY-ASP for ALL (June 24, 2018)
40 Table 15: KTE-X19 for ALL (June 4, 2018)
47 Table 16: Historical global sales, by drug ($m), 2014–18
48 Table 17: Forecasted global sales, by drug ($m), 2019–23
© Informa UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email email@example.com for further help or assistance.